Top of the morning to you, and a fine one it is. Clear blue skies and cool breezes are wafting over the Pharmalot campus, where are our recently arrived short person is sleeping and the official mascot is snoozing as well. This means we are free to focus on the matters at hand — rummaging through our to-do list and making cups of stimulation. Our choice today is wild mountain blueberry, a summer treat. Please feel free to join us. Meanwhile, here is the latest menu of tidbits to help you get started yourself. We hope your day is productive and meaningful. And of course, do keep in touch. We appreciate the insights and ideas. …
The United Nations Human Rights Council passed a non-binding resolution calling on countries to promote “timely, equitable and unhindered access” to safe, effective, quality and affordable medicines, vaccines, diagnostics and therapies for everyone, Health Policy Watch says. The move was hailed by advocacy groups, but opponents — such as the European Union, the U.K., and the U.S., which are home to major drugmakers — argued the World Health Organization should manage access. The resolution may have little practical impact, but could sway debate at the World Trade Organization over a proposal to relax intellectual property rules for making Covid-19 treatments and tests.
The New York attorney general argued that Teva Pharmaceutical lied to evade accountability for helping fuel the opioid crisis, Reuters notes. In a court filing, Attorney General Letitia James said new evidence showed that a senior Teva tax executive had in a sworn affidavit made “demonstrably false” representations that the parent company, which is based in Israel, did not promote or sell opioids in the U.S., or control the finances or activities of the U.S. unit. James also argued Teva transferred large sums of money from its American business, which created “real concern” the company might not pay damages following a verdict that the U.S. unit violated state public nuisance laws.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
